Upper Versus Middle‐Neck Involvement in TNM ‐9 Stage IB Nasopharyngeal Carcinoma: Implications for De‐Escalation and Intensification Strategies
Open Access
- 6 August 2026
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 15 (8) , e72166
Abstract
Background: TNM‐9 Stage IB nasopharyngeal carcinoma (NPC) encompasses markedly heterogeneous risk profiles, yet lacks reliable biomarkers to guide the choice between de‐escalation and intensification strategies. This study aimed to explore the prognostic significance of upper‐ and middle‐neck nodal involvement (UNI and MNI) in this population and how it affects treatment outcomes and prognosis. Methods: Patients with Stage IB NPC treated between June 2016 and December 2019 at our institution were included. Nodal levels were classified into UNI and MNI. Survival outcomes, including overall survival (OS), progression‐free survival (PFS), distant control (DC), and regional control (RC), were analyzed. Results: A total of 370 patients were analyzed, with 257 (69.5%) classified in the UNI group and 113 (30.5%) in the MNI group, respectively. MNI was found to be associated with significantly worse prognosis compared to UNI. Specifically, the MNI group had lower 5‐year OS (91.1% vs. 98.8%, p < 0.001), PFS (78.6% vs. 95.6%, p < 0.001), DC (90.2% vs. 98.8%, p < 0.001), and RC (93.3% vs. 98.4%, p = 0.005) than the UNI group. Association analysis revealed that nodal level was significantly associated with other known adverse prognostic factors, including the maximum diameter of positive lymph nodes, matted nodes, and high EBV‐DNA levels (all p < 0.001). Crucially, after multivariate adjustment, nodal level is the only independent prognostic factor. Conclusion: The nodal level was a critical factor in predicting patient outcomes in Stage IB NPC. These findings are hypothesis‐generating: UNI patients may represent a candidate population for prospective de‐escalation trials, whereas MNI patients may warrant evaluation of intensified or novel strategies in future studies. Prospective validation is required before any change in clinical management.Keywords
This publication has 18 references indexed in Scilit:
- Prognostic Value of Skull Base Foramen Invasion Subclassification in T Category Modification and Induction Chemotherapy Management for Nasopharyngeal Carcinoma: Post‐Hoc Analysis of a Dual‐Center Retrospective Cohort StudyAdvanced Science, 2024
- Ninth Version of the AJCC and UICC Nasopharyngeal Cancer TNM Staging ClassificationJAMA Oncology, 2024
- Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal CarcinomaJAMA, 2022
- Development and prospective validation of a risk score model in guiding individualized concurrent chemoradiotherapy in stage II nasopharyngeal carcinoma in intensity‐modulated radiotherapy eraCancer Medicine, 2021
- Modified reduced-volume intensity-modulated radiation therapy in non-metastatic nasopharyngeal carcinoma: A prospective observation seriesRadiotherapy and Oncology, 2021
- International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinomaRadiotherapy and Oncology, 2018
- Delineation of the neck node levels for head and neck tumors: A 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelinesRadiotherapy and Oncology, 2014
- Clinical outcomes for early-stage nasopharyngeal carcinoma with predominantly WHO II histology treated by intensity-modulated radiation therapy with or without chemotherapy in nonendemic region of ChinaHead & Neck, 2013
- Long-Term Outcomes of Early-Stage Nasopharyngeal Carcinoma Patients Treated With Intensity-Modulated Radiotherapy AloneInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Nasopharyngeal Carcinoma Treated With Reduced-Volume Intensity-Modulated Radiation Therapy: Report on the 3-Year Outcome of a Prospective SeriesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009